Literature DB >> 21039678

Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.

D M Evon1, K M Simpson, D Esserman, A Verma, S Smith, M W Fried.   

Abstract

BACKGROUND: Patients with hepatitis C viral (HCV) may perceive barriers to accessing speciality care for HCV, and these barriers may be related to depressive symptoms. AIM: To evaluate the relationship between barriers to care, demographics, and depressive symptoms.
METHODS: A cross-sectional analysis of 126 patients referred for HCV at two speciality HCV clinics. Barriers to care, depressive symptoms and sociodemographics were measured using standardized instruments. A retrospective chart review was conducted to collect clinical outcome data.
RESULTS: Depressive symptoms were reported in 26%. Common barriers included lack of personal financial resources; lack of HCV knowledge in the community; lack of professionals competent in HCV care; stigmatization of HCV; and long distances to clinics offering care. After we controlled for sociodemographics, depression accounted for an additional 7-18% of variability in all barriers (all p values <0.01). Lower depression, marital and employment status were associated with subsequent receipt of HCV treatment in 38% (45/120) of patients; perceived barriers were not.
CONCLUSIONS: Depression is independently associated with perceived barriers to care. Higher depressive scores, but not perceived barriers, were associated with nontreatment. Healthcare providers who diagnose HCV need to be cognizant of numerous perceived barriers to accessing HCV care, and the impact that depression may have on these perceptions and receipt of treatment.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21039678      PMCID: PMC3086670          DOI: 10.1111/j.1365-2036.2010.04460.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  41 in total

1.  Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences.

Authors:  S Reif; C E Golin; S R Smith
Journal:  AIDS Care       Date:  2005-07

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

3.  Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

Authors:  Yasushi Shiratori; Yoichi Ito; Osamu Yokosuka; Fumio Imazeki; Ryo Nakata; Naohide Tanaka; Yasuyuki Arakawa; Etsuko Hashimoto; Katsutaro Hirota; Haruhiko Yoshida; Yasuo Ohashi; Masao Omata
Journal:  Ann Intern Med       Date:  2005-01-18       Impact factor: 25.391

Review 4.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

5.  Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care.

Authors:  Catherine A Fleming; Sheila Tumilty; Jessica E Murray; David Nunes
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 6.  The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?

Authors:  J R Davidson; S E Meltzer-Brody
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

7.  Social-cognitive determinants of vaccination behavior against hepatitis B: an assessment among men who have sex with men.

Authors:  John B F de Wit; Raymond Vet; Merel Schutten; Jim van Steenbergen
Journal:  Prev Med       Date:  2005-06       Impact factor: 4.018

8.  Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care.

Authors:  Sanjeev Arora; Summers Kalishman; Karla Thornton; Denise Dion; Glen Murata; Paulina Deming; Brooke Parish; John Brown; Miriam Komaromy; Kathleen Colleran; Arthur Bankhurst; Joanna Katzman; Michelle Harkins; Luis Curet; Ellen Cosgrove; Wesley Pak
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

9.  Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale).

Authors:  E M Andresen; J A Malmgren; W B Carter; D L Patrick
Journal:  Am J Prev Med       Date:  1994 Mar-Apr       Impact factor: 5.043

10.  Barriers to care among persons living with HIV/AIDS in urban and rural areas.

Authors:  T G Heckman; A M Somlai; J Peters; J Walker; L Otto-Salaj; C A Galdabini; J A Kelly
Journal:  AIDS Care       Date:  1998-06
View more
  24 in total

1.  Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.

Authors:  Maryam Alavi; Jason Grebely; Gail V Matthews; Kathy Petoumenos; Barbara Yeung; Carolyn Day; Andrew R Lloyd; Ingrid Van Beek; John M Kaldor; Margaret Hellard; Gregory J Dore; Paul S Haber
Journal:  J Gastroenterol Hepatol       Date:  2012-05       Impact factor: 4.029

2.  Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients.

Authors:  Pooja Pundhir; Carol S North; Oluwatomilade Fatunde; Mamta K Jain
Journal:  J Community Health       Date:  2016-02

3.  Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.

Authors:  Christopher Woodrell; Jeffrey Weiss; Andrea Branch; Donald Gardenier; Katherine Krauskopf; Natalie Kil; Harold Paredes; Kian Bichoupan; Keith Sigel
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

Review 4.  Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?

Authors:  Donna M Evon; Carol E Golin; Michael W Fried; Francis J Keefe
Journal:  J Consult Clin Psychol       Date:  2012-06-25

5.  A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

Authors:  Diane S Morse; Miriam Schiff; Shabtay Levit; Rinat Cohen-Moreno; Geoffrey C Williams; Yehuda Neumark
Journal:  Subst Use Misuse       Date:  2012-01       Impact factor: 2.164

Review 6.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

7.  Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.

Authors:  Jason E Bonner; Denise A Esserman; Carol E Golin; Donna M Evon
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

Review 8.  Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Authors:  Luigi Elio Adinolfi; Riccardo Nevola; Giacomo Lus; Luciano Restivo; Barbara Guerrera; Ciro Romano; Rosa Zampino; Luca Rinaldi; Ausilia Sellitto; Mauro Giordano; Aldo Marrone
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

9.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

10.  A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

Authors:  Christopher E McGowan; Ali Monis; Bruce R Bacon; Josep Mallolas; Fernando L Goncales; Ioannis Goulis; Fred Poordad; Nezam Afdhal; Stefan Zeuzem; Teerha Piratvisuth; Patrick Marcellin; Michael W Fried
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.